Get the Stockscreener App
37.66
4.90%
-1.94
After Hours:
37.00
-0.66
-1.75%
Harrow Inc stock is traded at $37.66, with a volume of 609.02K.
It is down -4.90% in the last 24 hours and down -10.61% over the past month.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
See More
Previous Close:
$39.60
Open:
$40.58
24h Volume:
609.02K
Relative Volume:
0.84
Market Cap:
$1.39B
Revenue:
$154.15M
Net Income/Loss:
$-33.58M
P/E Ratio:
-39.23
EPS:
-0.96
Net Cash Flow:
$-20.74M
1W Performance:
-0.61%
1M Performance:
-10.61%
6M Performance:
+34.16%
1Y Performance:
-11.26%
1-Day Range:
$36.95
$41.24
1-Week Range:
$36.77
$41.55
52-Week Range:
$20.85
$50.72
Harrow Inc Stock (HROW) Company Profile
Name
Harrow Inc
Sector
Phone
615.733.4731
Address
1A BURTON HILLS BLVD, NASHVILLE, CA
Compare HROW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
37.66 | 1.47B | 154.15M | -33.58M | -20.74M | -0.96 |
|
ZTS
Zoetis Inc
|
115.89 | 51.60B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.51B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.60 | 42.35B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.28 | 28.04B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
474.72 | 20.52B | 3.08B | 1.24B | 1.07B | 25.61 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-25 | Initiated | BTIG Research | Buy |
| Jun-10-25 | Initiated | William Blair | Outperform |
| Feb-06-25 | Initiated | H.C. Wainwright | Buy |
| Dec-04-24 | Reiterated | B. Riley Securities | Buy |
| Apr-11-24 | Initiated | Craig Hallum | Buy |
| Sep-08-22 | Resumed | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-24-21 | Initiated | Aegis Capital | Buy |
| Jul-02-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Harrow Inc Stock (HROW) Latest News
Should I hold or sell Harrow Inc. stock in 2025Portfolio Gains Summary & Risk Managed Investment Entry Signals - newser.com
Harrow, Inc. Hits Day High with 7.65% Surge in Strong Intraday Performance - Markets Mojo
Why Harrow Inc. stock remains on watchlists2025 Earnings Surprises & Trade Opportunity Analysis Reports - newser.com
How Harrow Inc. stock performs in rising dollar environment2025 AllTime Highs & Risk Controlled Stock Alerts - newser.com
How Harrow Inc. stock reacts to job market dataJuly 2025 Decliners & Weekly Market Pulse Updates - newser.com
What insider trading reveals about Harrow Inc. stockBear Alert & Momentum Based Trading Signals - newser.com
Harrow, Inc. 2025 Q3ResultsEarnings Call Presentation (NASDAQ:HROW) 2025-11-19 - Seeking Alpha
How Harrow Inc. stock performs in rate cut cyclesEarnings Risk Summary & High Accuracy Trade Signal Alerts - newser.com
Harrow officially acquires Melt Pharmaceuticals - Eyes On Eyecare
Detecting price anomalies in Harrow Inc. with AIJuly 2025 Fed Impact & Consistent Profit Trading Strategies - newser.com
Will Harrow's (HROW) Return to Profitability Reshape Its Growth Narrative? - simplywall.st
Analyzing Harrow Inc. with risk reward ratio charts2025 Biggest Moves & Safe Swing Trade Setups - newser.com
Best data tools to analyze Harrow Inc. stockJuly 2025 PostEarnings & Consistent Return Investment Signals - newser.com
Harrow Completes Its Acquisition of Melt Pharmaceuticals - VisionMonday.com
What analysts say about Harrow Inc stockStock Price Targets & Affordable Growth Investments - earlytimes.in
Will Harrow Inc. stock pay special dividendsMarket Trend Report & Weekly Top Stock Performers List - newser.com
Harrow completes acquisition of Melt Pharmaceuticals By Investing.com - Investing.com Nigeria
Harrow (HROW) Finalizes Acquisition of Melt Pharmaceuticals - GuruFocus
Harrow Health Completes Acquisition of Melt Pharmaceuticals - TipRanks
[8-K] HARROW, INC. Reports Material Event | HROW SEC FilingForm 8-K - Stock Titan
Harrow Closes Melt Pharmaceuticals Acquisition - MarketScreener
Harrow Announces Closing of Acquisition of Melt Pharmaceuticals - The Manila Times
Harrow (Nasdaq: HROW) Closes Melt Deal, Sets MELT-300 NDA Filing for 2027 in U.S. - Stock Titan
What risks investors should watch in Harrow Inc. stockTrend Reversal & Accurate Entry/Exit Alerts - newser.com
Should you hold or exit Harrow Inc. now2025 EndofYear Setup & Daily Risk Controlled Trade Plans - newser.com
Why Harrow Inc. stock is in analyst buy zone2025 Price Momentum & Fast Gain Stock Trading Tips - newser.com
Key resistance and support levels for Harrow Inc.July 2025 Momentum & Low Risk Investment Opportunities - newser.com
Harrow Inc. stock volume spike explainedJuly 2025 News Drivers & Reliable Volume Spike Alerts - newser.com
Custom watchlist performance reports with Harrow Inc.July 2025 Recap & Low Risk Growth Stock Ideas - newser.com
Can Harrow Inc. stock sustain market leadership2025 Price Momentum & Risk Managed Trade Strategies - newser.com
Harrow Inc Stock (HROW) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.17%
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):